SZodixStudyAcademic Library

Dashboard Shelves Open access My library Inbox Notes Write Learn Alerts

More

Ask your library Notifications Quick cite Review

Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated

Barriers to entry, brand advertising, and generic entry in the US pharmaceutical industry · Study

ArticleShelves

ArticleBarriers to entry, brand advertising, and generic entry in the US pharmaceutical industry

Fiona Scott Morton2000

Article2000

Barriers to entry, brand advertising, and generic entry in the US pharmaceutical industry

Fiona Scott Morton

226 citations·0/0 files stored·International Journal of Industrial Organization

No readable copy stored yet — this record is metadata only.

No open-access location is known for this record yet.

Literature note Cite in a project Citation map

Pharmaceutical Economics and Policy Merger and Competition Analysis Consumer Market Behavior and Pricing

Abstract

No abstract was published for this record.

Paper brief

Loading…

Cite this work

Citation unavailable for this work.

BibTeX RIS CSL-JSON

No public copy is stored for this record, so only the metadata is cited.

Citations in this library

Citation map →

Stored only when both papers are in the corpus — 226 citations exist upstream.

References

1991Entry and Competition in Concentrated Markets 1980The Role of Investment in Entry-Deterrence 1977Entry, Capacity, Investment and Oligopolistic Pricing 1980Product differentiation advantages of pioneering brands 1992Brand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug Act 1990Entry in Monopoly Markets 1991Patent Expiration, Entry, and Competition in the U.S. Pharmaceutical Industry 1998The Importance of the Physician in the Generic versus Trade-Name Prescription Decision

Cited by

2011Strategic Entry Deterrence and the Behavior of Pharmaceutical Incumbents Prior to Patent Expiration 2010Consumer learning and heterogeneity: Dynamics of demand for prescription drugs after patent expiration 2014Measuring performance in off-patent drug markets: A methodological framework and empirical evidence from twelve EU Member States 2007Generic entry, price competition, and market segmentation in the prescription drug market 2010A DYNAMIC OLIGOPOLY STRUCTURAL MODEL FOR THE PRESCRIPTION DRUG MARKET AFTER PATENT EXPIRATION*

Related works

Explore the map →

Papers that cite the same references — the relational fallback while embeddings are still backfilling.

1991Pricing, Patent Loss and the Market For Pharmaceuticalsreport · 4 shared references 2001The Impact of Generic Drug Competition on Brand Name Market Shares – Evidence from Micro Dataarticle · 4 shared references 2007Strategic Entry Deterrence and the Behavior of Pharmaceutical Incumbents Prior to Patent Expirationreport · 4 shared references 2007Entry into Banking Markets and the Early‐Mover Advantagearticle · 4 shared references 2006The role of firm characteristics in pharmaceutical product launchesarticle · 4 shared references 2019Sharing economy and incumbents' pricing strategy: The impact of Airbnb on the hospitality industryarticle · 4 shared references

Details

Year2000

Typearticle

Published2000-10-01

VenueInternational Journal of Industrial Organization

ISSN-L0167-7187

Languageen

Citations226

Files0 public / 0

ShelfPharmaceutical Economics and Policy

Identifiers

doi10.1016/s0167-7187(98)00057-5

openalex_workW2148795255

Links

Imported from OpenAlex (CC0) — nothing here is generated.

2006Generic Competition in the US Pharmaceutical Industry

2016Regulation and welfare: evidence from paragraph IV generic entry in the pharmaceutical industry

2006Reference pricing of pharmaceuticals